

26th October, 2021

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,


Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2021

The presentation on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2021 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl : A/a



Q2 FY 2021-22

Revenues: Summary



Revenue: Summary

Revenues (Rs cr)	Q2 FY22	Q2 FY21	Gr%
India	1,087	963	13%
United States	284	327	-13%
Germany	251	261	-4%
Brazil	156	129	21%
Other countries	219	200	9%
Others (Inc. CRAMS)	140	139	1%
Total	2,137	2,017	6%

